Autopsy report · NCT02610543
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
Cause of deathSlow enrollment
“Study stopped prematurely due to enrolment challenges.”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 2 years 2 months before it stopped.
- 27 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- UCB Celltech
- Sponsor type
- Industry
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- UCB5857; Placebo
- Participants
- 27
- Sites
- 14
- Countries
- France, Italy, Spain, Sweden, United Kingdom
Trials that died the same way
- OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)
“Study stopped because slow enrolment.” - Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma
“The study has been halted due to the low enrolment rate.” - An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
“Study stopped due to lagging enrolment.” - Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
“The study was terminated early due to futility of enrolment and not for safety reasons.” - Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing
“Study was stopped due to funding and time constraints.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.